MiRNA-based therapies: Strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents

Future Medicinal Chemistry

Volumn 6, Issue 17, 2014, Pages 1967-1984

  Baumann, Volker ^a   Winkler, Johannes ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; MICRORNA; OLIGONUCLEOTIDE; POLYMER; SMALL INTERFERING RNA; DOUBLE STRANDED RNA; DRUG CARRIER; LOCKED NUCLEIC ACID;

BACTERIOPHAGE; CONJUGATE; DOWN REGULATION; EXOSOME; GENE DELIVERY SYSTEM; GENE OVEREXPRESSION; HUMAN; LIPOSOMAL DELIVERY; ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; GENETICS; METABOLISM; NEOPLASMS; VIRUS DISEASES;

DRUG CARRIERS; HUMANS; LIPOSOMES; MICRORNAS; NEOPLASMS; OLIGONUCLEOTIDES; POLYMERS; RNA, DOUBLE-STRANDED; RNA, SMALL INTERFERING; VIRUS DISEASES;

EID: 84919792381     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.116     Document Type: Review

References (175)

1. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5(2), 123-132 (2006
2. Parhofer KG. Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. Core Evid. 7, 29-38 (2012
3. Grillone LR, Lanz R. Fomivirsen. Drugs Today (Barc.) 37(4), 245-255 (2001
4. Dirin M, Winkler J. Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides. Expert Opin. Biol. Ther. 13(6), 875-888 (2013
5. Scully MA, Pandya S, Moxley RT. Review of Phase II and Phase III clinical trials for Duchenne muscular dystrophy. Expert Opin. Orphan Drugs 1(1), 33-46 (2013
6. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature 391(6669), 806-811 (1998
7. Winkler J. Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides. Ther. Deliv. 2(7), 891-905 (2011
8. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8(2), 129-138 (2009
9. Semple SC, Akinc A, Chen J et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28(2), 172-176 (2010
10. Winkler J. Oligonucleotide conjugates for therapeutic applications. Ther. Deliv. 4(7), 791-809 (2013
11. Gomes-da-Silva LC, Fonseca NA, Moura V, Pedroso de Lima MC, Simoes S, Moreira JN. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Acc. Chem. Res. 45(7), 1163-1171 (2012
12. Akinc A, Querbes W, De S et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18(7), 1357-1364 (2010
13. Yeung ML, Jeang KT. MicroRNAs and cancer therapeutics. Pharm. Res. 28(12), 3043-3049 (2011
14. Pritchard CC, Kroh E, Wood B et al. Blood cell origin of circulating micrornas. a cautionary note for cancer biomarker studies. Cancer Prev. Res. (Phila.) 5(3), 492-497 (2012
15. Janssen HLA, Reesink HW, Lawitz EJ et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368(18), 1685-1694 (2013
16. Gebert LFR, Rebhan MAE, Crivelli SEM, Denzler R, Stoffel M, Hall J. Miravirsen (SPC3649) can inhibit the biogenesis of miR?122. Nucleic Acids Res. 42(1), 609-621 (2014
17. Liu C, Kelnar K, Liu B et al. The microRNA miR?34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 17(2), 211-215 (2011
18. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843-854 (1993
19. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 294, 858-862 (2001
20. Ruvkun G. Glimpses of a tiny RNA world. Science 797-799 (2001
21. Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, Snyder M. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57-74 (2012
22. Lee Y, Kim M, Han J et al MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 23, 4051-4060 (2004
23. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat. Struct. Mol. Biol. 13, 1097-1101 (2006
24. Johnson SM, Lin S-Y, Slack FJ. The time of appearance of the C. elegans let-7 microRNA is transcriptionally controlled utilizing a temporal regulatory element in its promoter. Dev. Biol. 259, 364-379 (2003
25. Zhao X, Zhang H, Li L. Identification and analysis of the proximal promoters of microRNA genes in Arabidopsis. Genomics 101, 187-194 (2013
26. Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J. 21, 4663-4670 (2002
27. Han J, Lee Y, Yeom K-H et al. Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell 125, 887-901 (2006
28. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 17, 3011-3016 (2003
29. Lund E, Güttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science 303, 95-98 (2004
30. Ketting RF, Fischer SEJ, Bernstein E, Sijen T, Hannon GJ, Plasterk RHA. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev. 15(20), 2654-2659 (2001
31. Zhang H, Kolb FA, Brondani V, Billy E, Filipowicz W. Human Dicer preferentially cleaves dsRNAs at their termini without a requirement for ATP. EMBO J. 21, 5875-5885 (2002
32. Xie Z, Kasschau K, Carrington J. Negative feedback regulation of dicer-like1 in Arabidopsis by microRNA-guided mRNA degradation. Curr. Biol. 13, 784-789 (2003
33. Chendrimada TP, Gregory RI, Kumaraswamy E et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 436(7051), 740-744 (2005
34. Hutvagner G. Small RNA asymmetry in RNAi: function in RISC assembly and gene regulation. FEBS Lett. 579, 5850-5857 (2005
35. Rand TA, Ginalski K, Grishin NV, Wang X. Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity. Proc. Natl Acad. Sci. USA 101, 14385-14389 (2004
36. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 20, 515-524 (2006
37. Saxena S, Jónsson ZO, Dutta A. Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J. Biol. Chem. 278, 44312-44319 (2003
38. Krek A, Grün D, Poy MN et al. Combinatorial microRNA target predictions. Nat. Genet. 37, 495-500 (2005
39. Petersen CP, Bordeleau M-E, Pelletier J, Sharp PA. Short RNAs repress translation after initiation in mammalian cells. Mol. Cell 21, 533-542 (2006
40. Sotillo E, Thomas-Tikhonenko A. Shielding the messenger (RNA): microRNA-based anticancer therapies. Pharmacol. Ther. 131, 18-32 (2011
41. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15-20 (2005
42. Baek J, Kang S, Min H. MicroRNA-targeting therapeutics for hepatitis C. Arch. Pharm. Res. 37(3), 299-305 (2014
43. Shen J, Xia W, Khotskaya YB et al. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 497, 383-387 (2013
44. Almeida MI, Reis RM, Calin GA. MicroRNA history: discovery, recent applications, and next frontiers. Mutat. Res. 717, 1-8 (2011
45. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 11, 849-864 (2011
46. Di Leva G, Croce CM. miRNA profiling of cancer. Curr. Opin. Genet. Dev. 23, 3-11 (2013
47. Malumbres M. miRNAs and cancer: an epigenetics view. Mol. Aspects Med. 34, 863-874 (2013
48. Meyer FRL, Grausgruber H, Binter C et al. Cross-platform microarray meta-analysis for the mouse jejunum selects novel reference genes with highly uniform levels of expression. PLoS ONE 8, e63125 (2013
49. Schroeder A, Mueller O, Stocker S et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol. Biol. 7, 3 (2006
50. Peltier H, Latham G. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid. RNA 14(5), 844-852 (2008
51. Solanas M, Moral R, Escrich E. Unsuitability of using ribosomal RNA as loading control for Northern blot analyses related to the imbalance between messenger and ribosomal RNA content in rat mammary tumors. Anal. Biochem. 288, 99-102 (2001
52. Morlan JD, Qu K, Sinicropi DV. Selective depletion of rRNA enables whole transcriptome profiling of archival fixed tissue. PLoS ONE 7, e42882 (2012
53. Adiconis X, Borges-Rivera D, Satija R et al. Comparative analysis of RNA sequencing methods for degraded or lowinput samples. Nat. Methods 10, 623-629 (2013
54. Gee HE, Buffa FM, Camps C et al. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br. J. Cancer 104, 1168-1177 (2011
55. Chen C, Ridzon Da, Broomer AJ et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33, e179 (2005
56. Varkonyi-Gasic E, Wu R, Wood M, Walton EF, Hellens RP. Protocol: a highly sensitive RT-PCR method for detection and quantification of microRNAs. Plant Methods 3, 12 (2007
57. Kang K, Xiaoying Z, Hongtao L et al. A Novel Real-Time PCR Assay of microRNAs Using S-Poly(T), a Specific Oligo(dT) Reverse Transcription Primer with Excellent Sensitivity and Specificity. PLoS ONE 7(11), e48536 (2012
58. Bustin SA, Benes V, Garson JA et al. The MIQE guidelines. minimum information for publication of quantitative realtime PCR experiments. Clin. Chem. 55, 611-622 (2009
59. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99, 15524-15529 (2002
60. Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat. Rev. Clin. Onocl. 11(3), 145-156 (2014
61. Melo SA, Kalluri R. Molecular Pathways: microRNAs as cancer therapeutics. Clin. Cancer Res. 18(16), 4234-4239 (2012
62. Lu J, Getz G, Miska E, Alvarez-Saavedra E. MicroRNA expression profiles classify human cancers. Nature 435, (2005
63. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18, 997-1006 (2008
64. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer 127, 118-126 (2010
65. Etheridge A, Lee I, Hood L, Galas D, Wang K. Extracellular microRNA: a new source of biomarkers. Mutat. Res. 717, 85-90 (2011
66. Jansson MD, Lund AH. MicroRNA and cancer. Mol. Oncol. 6, 590-610 (2012
67. Lopez-Camarillo C, Marchat LA, Arechaga-Ocampo E et al. MetastamiRs. non-coding microRNAs driving cancer invasion and metastasis. Int. J. Mol. Sci. 13, 1347-1379 (2012
68. Bouyssou JMC, Manier S, Huynh D, Issa S, Roccaro AM, Ghobrial IM. Regulation of microRNAs in cancer metastasis. Biochim. Biophys. Acta 1845(2), 255-265 (2014
69. Takahashi R-U, Miyazaki H, Ochiya T. The role of microRNAs in the regulation of cancer stem cells. Front. Genet. 4, 295 (2014
70. Xia H, Hui KM. MicroRNAs involved in regulating epithelial-mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics. Cancer Gene Ther. 19, 723-730 (2012
71. Liu J, Zheng M, Tang YL, Liang X-H, Yang Q. MicroRNAs, an active and versatile group in cancers. Int. J. Oral Sci. 3, 165-175 (2011
72. Chan Ja, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65, 6029-6033 (2005
73. Cimmino A, Calin G. miR?15 and miR?16 induce apoptosis by targeting BCL2. Proc. Natl Acad. Sci. USA 103, (2005
74. Johnson SM, Grosshans H, Shingara J et al. RAS is regulated by the let-7 microRNA family. Cell 120, 635-647 (2005
75. Calin GA, Sevignani C, Dumitru CD et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl Acad. Sci. USA 101, 2999-3004 (2004
76. Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J. Clin. Invest. 123(6), 2395-2407 (2013
77. Pan X, Wang Z-X, Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol. Ther. 10(12), 1224-1232 (2010
78. Bader AG. miR?34 - a microRNA replacement therapy is headed to the clinic. Front. Genet. 3, 120 (2012
79. Guo J, Xia B, Meng F, Lou G. miR?137 suppresses cell growth in ovarian cancer by targeting AEG-1. Biochem. Biophys. Res. Commun. 441, 357-363 (2013
80. Zhu X, Li Y, Shen H et al. miR?137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6. FEBS Lett. 587, 73-81 (2013
81. Law PTY, Ching AKK, Chan AWH et al. MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. Carcinogenesis 33, 1134-1141 (2012
82. Wang Y, Hu C, Cheng J et al. MicroRNA-145 suppresses hepatocellular carcinoma by targeting IRS1 and its downstream Akt signaling. Biochem. Biophys. Res. Commun. 446, 1255-1260 (2014
83. Zheng L, Pu J, Qi T et al. miRNA-145 targets v-ets erythroblastosis virus E26 oncogene homolog 1 to suppress the invasion, metastasis, and angiogenesis of gastric cancer cells. Mol. Cancer Res. 11, 182-193 (2013
84. Chan SH, Huang WC, Chang JW et al. MicroRNA-149 targets GIT1 to suppress integrin signaling and breast cancer metastasis. Oncogene 33(36), 4496-4507 (2014
85. Jin L, Hu WL, Jiang CC et al. MicroRNA-149. a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc. Natl Acad. Sci. USA 108(38), 15840-15845 (2011
86. Chen Y, Ke G, Han D, Liang S, Yang G, Wu X. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD. Exp. Cell Res. 320, 12-20 (2014
87. Liu M, Wang J, Huang H, Hou J, Zhang B, Wang A. miR?181a-Twist1 pathway in the chemoresistance of tongue squamous cell carcinoma. Biochem. Biophys. Res. Commun. 441, 364-370 (2013
88. Wang H, Bian S, Yang CS. Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR?210 expression caused by stabilizing HIF-1?. Carcinogenesis 32, 1881-1889 (2011
89. Alajez NM, Lenarduzzi M, Ito E et al. MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 71, 2381-2391 (2011
90. Yao Y, Xue Y, Ma J et al. MiR-330-mediated regulation of SH3GL2 expression enhances malignant behaviors of glioblastoma stem cells by activating ERK and PI3K/AKT signaling pathways. PLoS ONE 9, e95060 (2014
91. Li Y, Zhu X, Xu W, Wang D, Yan J. miR?330 regulates the proliferation of colorectal cancer cells by targeting Cdc42. Biochem. Biophys. Res. Commun. 431, 560-565 (2013
92. Peng Y, Liu YM, Li LC, Wang LL, Wu XL. MicroRNA-338 inhibits growth, invasion and metastasis of gastric cancer by targeting NRP1 expression. PLoS ONE 9, e94422 (2014
93. Zhou P, Huang G, Zhao Y et al. MicroRNA-363-mediated downregulation of S1PR1 suppresses the proliferation of hepatocellular carcinoma cells. Cell Signal 26, 1347-1354 (2014
94. Yang F, Nam S, Brown CE et al. A novel berbamine derivative inhibits cell viability and induces apoptosis in cancer stem-like cells of human glioblastoma, via upregulation of miRNA-4284 and JNK/AP-1 signaling. PLoS ONE 9, e94443 (2014
95. Weber B, Stresemann C, Brueckner B, Lyko F. Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle 6(9), 1001-1005 (2007
96. Costello JF, Frühwald MC, Smiraglia DJ et al. Aberrant CpG-island methylation has non-random and tumour-typespecific patterns. Nat. Genet. 24, 132-138 (2000
97. Keshet I, Schlesinger Y, Farkash S et al. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat. Genet. 38, 149-153 (2006
98. Kunej T, Godnic I, Ferdin J, Horvat S, Dovc P, Calin GA. Epigenetic regulation of microRNAs in cancer: an integrated review of literature. Mutat. Res. 717, 77-84 (2011
99. Saito Y, Liang G, Egger G et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9, 435-443 (2006
100. Zhang L, Volinia S, Bonome T et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc. Natl Acad. Sci. USA 105, 7004-7009 (2008
101. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res. 66, 1277-1281 (2006
102. Schepeler T, Reinert JT, Ostenfeld MS et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res. 68, 6416-6424 (2008
103. Varnholt H, Drebber U, Schulze F et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 47, 1223-1232 (2008
104. Hansen TB, Jensen TI, Clausen BH et al. Natural RNA circles function as efficient microRNA sponges. Nature 495, 384-388 (2013
105. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465, 1033-1038 (2010
106. Wang L, Guo Z-Y, Zhang R et al. Pseudogene OCT4-pg4 functions as a natural micro RNA sponge to regulate OCT4 expression by competing for miR?145 in hepatocellular carcinoma. Carcinogenesis 34, 1773-1781 (2013
107. Wang Y, Zheng X, Zhang Z et al. MicroRNA-149 inhibits proliferation and cell cycle progression through the targeting of ZBTB2 in human gastric cancer. PLoS ONE 7(10), e41693 (2012
108. Ke Y, Zhao W, Xiong J, Cao R. miR?149 inhibits non-smallcell lung cancer cells EMT by targeting FOXM1. Biochem. Res. Int. 2013, 506731 (2013
109. Nana-Sinkam SP, Croce CM. MicroRNAs as therapeutic targets in cancer. Transl. Res. 157, 216-225 (2011
110. Jansson MD, Lund AH. MicroRNA and cancer. Mol. Oncol. 6(6), 590-610 (2012
111. Ling H, Fabbri M, Calin GA. MicroRNAs and other noncoding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov. 12(11), 847-865 (2013
112. Kantharidis P, Wang B, Carew RM, Lan HY. Diabetes complications: The microRNA perspective. Diabetes 60(7), 1832-1837 (2011
113. Latreille M, Hausser J, Stützer I et al. MicroRNA-7a regulates pancreatic ? cell function. J. Clin. Invest. 124(6), 2722-2735 (2014
114. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat. Rev. Drug Discov. 11(11), 860-872 (2012
115. Beveridge NJ, Cairns MJ. MicroRNA dysregulation in schizophrenia. Neurobiol. Dis. 46(2), 263-271 (2012
116. Leidinger P, Backes C, Deutscher S et al. A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol. 14(7), R78 (2013
117. Gaughwin PM, Ciesla M, Lahiri N, Tabrizi SJ, Brundin P, Björkqvist M. Hsa-miR?34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease. Hum. Mol. Genet. 20(11), 2225-2237 (2011
118. Gandhi R, Healy B, Gholipour T et al. Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis. Ann. Neurol. 73(6), 729-740 (2013
119. Henry JC, Azevedo-Pouly AC, Schmittgen TD. microRNA replacement therapy for cancer. Pharm. Res. 28(12), 3030-3042 (2011
120. Lennox KA, Behlke MA. Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther. 18(12), 1111-1120 (2011
121. Disney MD, Yildirim I, Childs-Disney JL. Methods to enable the design of bioactive small molecules targeting RNA. Org. Biomol. Chem. 12(7), 1029-1039 (2014
122. Bramsen JB, Laursen MB, Nielsen AF et al. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res. 37(9), 2867-2881 (2009
123. Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J. Control. Release 172(3), 962-974 (2013
124. Zeng Y, Wagner E, Cullen B. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol. Cell 9, 1327-1333 (2002
125. Yi R, Doehle B, Qin Y. Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs. RNA 11( 2), 220-226 (2005
126. Kasinski AL, Slack FJ. Arresting the culprit: Targeted antagomir delivery to sequester oncogenic miR?221 in HCC. Mol. Ther. Nucleic Acids 1, e12 (2012
127. Zamaratski E, Pradeepkumar PI, Chattopadhyaya J. A critical survey of the structure-function of the antisense oligo/RNA heteroduplex as substrate for RNase H. J. Biochem. Biophys. Methods 48(3), 189-208 (2001
128. Obad S, dos Santos CO, Petri A et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet. 43(4), 371-378 (2011
129. Braasch DA, Corey DR. Locked nucleic acid (LNA): finetuning the recognition of DNA and RNA. Chem. Biol. 8(1), 1-7 (2001
130. Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat. Rev. Drug Discov. 9(1), 57-67 (2010
131. Eckstein F. Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them?. Antisense Nucleic Acid Drug Dev. 10(2), 117-121 (2000
132. Krutzfeldt J, Rajewsky N, Braich R et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438(7068), 685-689 (2005
133. Fabani MM, Gait MJ. miR?122 targeting with LNA/2'-Omethyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA 14(2), 336-346 (2008
134. van Rooij E. The art of microRNA research. Circ. Res. 108(2), 219-234 (2011
135. Henshall DC. Antagomirs and microRNA in status epilepticus. Epilepsia 54, 17-19 (2013
136. Kurowska-Stolarska M, Alivernini S, Ballantine LE et al. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc. Natl Acad. Sci. USA 108(27), 11193-11198 (2011
137. Garchow BG, Bartulos Encinas O, Leung YT et al. Silencing of microRNA?21 in vivo ameliorates autoimmune splenomegaly in lupus mice. EMBO Mol. Med. 3(10), 605-615 (2011
138. Rayner KJ, Sheedy FJ, Esau CC et al. Antagonism of miR?33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J. Clin. Invest. 121(7), 2921-2931 (2011
139. Selvamani A, Sathyan P, Miranda RC, Sohrabji F. An antagomir to microRNA Let7f promotes neuroprotection in an ischemic stroke model. PLoS ONE 7(2), e32662 (2012
140. Ebert MS, Sharp PA. MicroRNA sponges: progress and possibilities. RNA 16(11), 2043-2050 (2010
141. Gumireddy K, Young DD, Xiong X, Hogenesch JB, Huang Q, Deiters A. Small-molecule inhibitors of microRNA miR?21 function. Angew. Chem. Int. Ed. Engl. 47(39), 7482-7484 (2008
142. Deiters A. Small molecule modifiers of the microRNA and RNA interference pathway. AAPS J. 12(1), 51-60 (2010
143. Velagapudi SP, Gallo SM, Disney MD. Sequence-based design of bioactive small molecules that target precursor microRNAs. Nat. Chem. Biol. 10(4), 291-297 (2014
144. Young DD, Connelly CM, Grohmann C, Deiters A. Small molecule modifiers of microRNA miR?122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. J. Am. Chem. Soc. 132(23), 7976-7981 (2010
145. Velagapudi SP, Disney MD. Two-dimensional combinatorial screening enables the bottom-up design of a microRNA-10b inhibitor. Chem. Commun. (Camb) 50(23), 3027-3029 (2014
146. Zhang Q, Zhang C, Xi Z. Enhancement of RNAi by a small molecule antibiotic enoxacin. Cell Res. 18(10), 1077-1079 (2008
147. Melo S, Villanueva A, Moutinho C et al. Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc. Natl Acad. Sci. USA, 108(11), 4394-4399 (2011
148. Smalheiser NR, Zhang H, Dwivedi Y. Enoxacin elevates microRNA levels in rat frontal cortex and prevents learned helplessness. Front. Psychiatry 5, 6 (2014
149. Kota J, Chivukula RR, O'Donnell KA et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137(6), 1005-1017 (2009
150. Piao L, Zhang M, Datta J et al. Lipid-based nanoparticle delivery of Pre-miR?107 inhibits the tumorigenicity of head and neck squamous cell carcinoma. Mol. Ther. 20(6), 1261-1269 (2012
151. Hsu S-H, Yu B, Wang X et al. Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor. Nanomed. Nanotechnol. 9(8), 1169-1180 (2013
152. Akinc A, Zumbuehl A, Goldberg M et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26(5), 561-569 (2008
153. Tseng Y-C, Mozumdar S, Huang L. Lipid-based systemic delivery of siRNA. Adv. Drug Deliv. Rev. 61(9), 721-731 (2009
154. Wu Y, Crawford M, Yu B, Mao Y, Nana-Sinkam SP, Lee LJ. MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol. Pharm. 8(4), 1381-1389 (2011
155. Wu Y, Crawford M, Mao Y et al. Therapeutic delivery of microRNA-29b by cationic lipoplexes for lung cancer. Mol. Ther. Nucleic Acids 2, e84 (2013
156. Shi S, Han L, Gong T, Zhang Z, Sun X. Systemic delivery of microRNA-34a for cancer stem cell therapy. Angew. Chem. Int. Ed. Engl. 52(14), 3901-3905 (2013
157. Chen Y, Zhu X, Zhang X, Liu B, Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther. 18(9), 1650-1656 (2010
158. Trang P, Wiggins JF, Daige CL et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 19(6), 1116-1122 (2011
159. Bolcato-Bellemin A-L, Bonnet M-E, Creusat G, Erbacher P, Behr JP. Sticky overhangs enhance siRNA-mediated gene silencing. Proc. Natl Acad. Sci. USA 104(41), 16050-16055 (2007
160. Liu X, Liu C, Laurini E et al. Efficient delivery of sticky siRNA and potent gene silencing in a prostate cancer model using a generation 5 triethanolamine-core PAMAM dendrimer. Mol. Pharm. 9(3), 470-481 (2011
161. Chiou GY, Cherng JY, Hsu HS et al. Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. J. Control. Release 159(2), 240-250 (2012
162. Yang YP, Chien Y, Chiou GY et al. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials 33(5), 1462-1476 (2012
163. Hwang do W, Son S, Jang J et al. A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 32(21), 4968-4975 (2011
164. Fattal E, Barratt G. Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. Br. J. Pharmacol. 157(2), 179-194 (2009
165. Babar IA, Cheng CJ, Booth CJ et al. Nanoparticle-based therapy in an in vivo microRNA-155 (miR?155)-dependent mouse model of lymphoma. Proc. Natl Acad. Sci. USA 109(26), e1695-e1704 (2012
166. Cheng CJ, Saltzman WM. Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing. Mol. Pharm. 9(5), 1481-1488 (2012
167. Tivnan A, Orr WS, Gubala V et al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS ONE 7(5), e38129 (2012
168. Soutschek J, Akinc A, Bramlage B et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432(7014), 173-178 (2004
169. Regulus Therapeutics. www.regulusrx.com
170. Montecalvo A, Larregina AT, Shufesky WJ et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 119(3), 756-766 (2012
171. Hagiwara K, Ochiya T, Kosaka N. A paradigm shift for extracellular vesicles as small RNA carriers: from cellular waste elimination to therapeutic applications. Drug Deliv. Transl. Res. 4, 31-37 (2014
172. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29(4), 341-345 (2011
173. Ohno SI, Takanashi M, Sudo K et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 21(1), 185-191 (2013
174. Pan Y, Zhang Y, Jia T, Zhang K, Li J, Wang L. Development of a microRNA delivery system based on bacteriophage MS2 virus-like particles. FEBS J. 279(7), 1198-1208 (2012
175. Ye X, Liu Z, Hemida MG, Yang D. Targeted delivery of mutant tolerant anti-coxsackievirus artificial microRNAs using folate conjugated bacteriophage Phi29 pRNA. PLoS ONE 6(6), e21215 (2011